The possible protective effect of L-carnitine on tilmicosin-induced cardiotoxicity in mice

Journal of Veterinary Medicine Series A: Physiology Pathology Clinical Medicine

Volumn 54, Issue 3, 2007, Pages 144-146

  Kart, A ^a   Yapar, K ^a   Karapehlivan, M ^a   Citil, M ^a  

^a KAFKAS UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARNITINE; CREATINE KINASE; DRUG DERIVATIVE; GLUTATHIONE; MACROLIDE; MALONALDEHYDE; N ACETYLNEURAMINIC ACID; TILMICOSIN; TYLOSIN; VITAMIN B COMPLEX;

ANIMAL; ANIMAL DISEASE; BAGG ALBINO MOUSE; BLOOD; DRUG EFFECT; HEART; MOUSE; RANDOMIZATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CARNITINE; CREATINE KINASE; GLUTATHIONE; HEART; INJECTIONS, SUBCUTANEOUS; MACROLIDES; MALONDIALDEHYDE; MICE; MICE, INBRED BALB C; N-ACETYLNEURAMINIC ACID; RANDOM ALLOCATION; TYLOSIN; VITAMIN B COMPLEX;

MUS;

EID: 33947403954     PISSN: 0931184X     EISSN: 14390442     Source Type: Journal    
DOI: 10.1111/j.1439-0442.2007.00897.x     Document Type: Review

References (25)

1. Altunok, V., E. Yazar, M. Elmas, B. Tras, A. L. Bas, and R. Col, 2002: Investigation of haematological and biochemical side effects of tilmicosin in healthy New Zealand Rabbits. J. Vet. Med. B 49, 68-70.
2. Ashraf, V., G. Franco, I. Syed, B. Zbigniew, and A. Syed, 2002: The protective role of L-carnitine against neurotoxicity evoked by drug of abuse, methamphetamine, could be related to mitochondrial dysfunction. Ann. N. Y. Acad. Sci. 965, 225-232.
3. Berkan, O., M. K. Gol, I. Gunay, and M. Sagaban, 2002: Sialic acid is an indicator of inflammation due to cardiopulmonary bypass but not myocardial damage. J. Cardiovasc. Surg. 43, 489-493.
4. Beutler, E., O. Duran, and B. M. Kelley, 1963: Improved method for determination of blood Glutathione. J. Lab. Clin. Mod. 28, 882-888.
5. Brass, E. M., 2000: Supplemental carnitine and exercise. Am. J. Clin. Nutr. 72, 618-623.
6. Christenson, R. H., and H. E. M. Azzazy, 1998: Biochemical markers of the acute coronary syndromes. Clin. Chem. 44, 1855-1864.
7. De Leonardis, V., B. Neri, S. Bacalli, and P. Cinelli, 1985: Reduction of cardiac toxicity of anthracyclines by L-carnitine: preliminary overview of clinical data. Int. J. Clin. 5, 137-142.
8. Hagen, T. M., C. M. Wehr, and B. N. Ames, 1998: Mitochondrial decay in ageing. Reversal through supplementation of acetyl-L-carnitine and N-tetri-butyle-alpha-phenyl-nitrone. Ann. N. Y. Acad. Sci. 854, 214-223.
9. Jordan, W. H., R. A. Byrd, R. L. Cochrane, G. K. Hanasono, J. A. Hoyt, B. W. Main, R. D. Meychoff, and R. D. Sarazan, 1993: A review of the toxicology of the antibiotic Micotil 300. Vet. Hum. Toxicol. 35, 151-158.
10. +-ATPase glutathione-s-transferase and multiple unit activity and reduces lipid peroxidation and lipofuscin concentration in aged rat brain regions. Neurosci. Lett. 301, 1-4.
11. Kelly, G. S., 1998: L-Carnitine: therapeutic applications of a conditionally-essential amino acid. Altern. Med. Rev. 3, 345-360.
12. Lindberg, G., G. A. Eklund, B. Gullberg, and L. Rastam, 1991 : Serum sialic acid concentration and cardiovascular mortality. Br. Med. J. 302, 143-146.
13. Main, B. W., J. R. Means, L. E. Rinkema, W. C. Smith, and R. D. Sarazan, 1996: Cardiovascular effects of the macrolide antibiotic tilmicosin, administered alone and in combination with propranolol or dobutamine, in conscious unrestrained dogs. J. Vet Pharmacol. Therap. 19, 225-232.
14. Me Guigan, M. A., 1994: Human exposures to tilmicosin. Vet. Hum. Toxicol. 36, 306-308.
15. Pallor, M. S., J. R. Holdal, and T. F. Ferris, 1984: Oxygen free radicals in ischemi acute renal failure in the rat. J. Clin. Invest. 74, 1156-1164.
16. Paterna, S., G. Furitano, L. Scaffidi, C. Barbarino, D. Campisi, G. Parisi, and I. Carreca, 1984: Effects of L-carnitine on adriamycin-induced cardiomyopathy in rabbit. Int. J. Tissue React. 6, 91-95.
17. Prescott, J., and D. Baggot, 1993: Lincosamides, macrolides, and pleuromutilins. In: Prescott, J., and D. Baggot (eds), Antimicrobial Therapy in Veterinary Medicine, pp. 179-204. Iowa State University Press, Ames, IA.
18. Saks, V., P. Dzeja, U. Schlattner, M. Vendelin, A. Terzic, and T. Wallimann, 2006: Cardiac system bioenergetics: metabolic basis of the Frank-Starling law. J. Physiol. 571, 253-273.
19. Sillanaukee, P., M. Ponnio, and I. P. Jaaskelainen, 1999: Occurrence of sialic acids in healthy humans and different disorders. Eur. J. Clin. Nutr. 29, 413-425.
20. Sydow, G., 1985: A simplified quick method for determination of sialic acid in serum. Biomed. Biochim. Acta. 44, 1721-1723.
21. Von Essen, S., J. Spencer, B. Hass, P. List, and S. Seifert, 2003: Unintentional human exposure to tilmicosin (Micotil 300®). J. Toxicol. Clin. Toxicol. 41, 229-233.
22. Yazar, E., Y. O. Birdane, M. Elmas, B. Tras, and A. L. Bas, 2002a: Effect of tilmicosin on serum creatine kinase, creatine kinase-MB and troponin I levels in New Zeland White Rabbits. Arch. Geflügelk. 66, 1-3.
23. Yazar, E., V. Altunok, M. Elmas, B. Tras, A. L. Bas, and V. Ozdemir, 2002b: The effect of tilmicosin on cardiac Superoxide dismutase and gluthatione peroxidase activities. J. Vet. Med. B 49, 209-210.
24. Yazar, E., E. Oztekin, A. Sivrikaya, R. Col, M. Elmas, and A. L. Bas, 2004: Effects of different doses of tilmicosin on malondialdehyde and Glutathione concentrations in mice. Acta Vet. Brno 73, 69-72.
25. Yoshoiko, T., K. Kawada, and T. Shimada, 1979: Lipid peroxidation in maternal and cord blood and protective mechanism against actived-oxygen toxicity in the blood. Am. J. Obstet. Gynecol. 135, 372-376.